Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAndrew Tan, PhD
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Positions outside Yale
Deputy Director, Center for Neuroscience and Regeneration Research, US Department of Veteran Affairs
Biography
My research interests focus on spinal cord injury (SCI) pathology, particularly mechanisms underlying neuropathic pain and spastic movement disorders. My long-term goal is to identify and assess novel targets and strategies that can help restore normal function after SCI. My hope is that our efforts will eventually lead to more effective and safe clinical therapies.
As the Principal Investigator (PI) of US Federal awards and privately funded grants, I have applied my expertise toward managing the execution of a broad range of projects, and have developed strong collaborations with domestic and international teams. As an Associate Director of the Center for Neuroscience and Regeneration Research at the West Haven VA Medical Center, I currently supervise a wonderful team of students, postdocs, and junior faculty in our SCI/D research program. Our published research has utilized in vitro and in vivo approaches, including a combination of anatomical analyses, behavioral assessment, viral-based gene therapy, and whole-animal electrophysiological techniques.
Over the past decade, my team has laid the groundwork demonstrating that maladaptive dendritic spine remodeling within nociceptive or motor reflex circuits underlies SCI-induced hyperexcitability disorders, i.e., neuropathic pain and spasticity. This body of work has also demonstrated for the first time that the Rac1-PAK1 pathway is a key mechanism involved in maintaining chronic pain and spinal motor reflex dysfunction. A core implication of these insights is that dendritic spine profiles may serve as a morphological correlate for sensory-motor hyperexcitability disorders, and could be used to predict therapeutic-drug response. Recently, we pioneered the use of long-term, in vivo two-photon imaging assays that we now use to investigate the relationship between dendritic spine dynamics in the spinal dorsal horn and neuropathic pain.
Appointments
Neurology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Associate
- Columbia University/The City College (CUNY) (2011)
- Postdoctoral Fellow
- Yale University (2008)
- PhD
- Stony Brook University (2006)
- BS
- University of Rochester, Neuroscience (2001)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-0099-8814
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Stephen Waxman, MD, PhD
Sierra Dawn Kauer
Lakshmi Bangalore, PhD
Jared King
Former YSMCurtis Benson
Former YSMPeng Zhao, PhD
Spinal Cord Injuries
Publications
2026
Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation
Meltzer M, Zamir M, Tzuri N, Tan A, Geva M, Hayden M, Lichtenstein R. Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via Sigma-1 Receptor Activation. International Journal Of Molecular Sciences 2026, 27: 3489. PMID: 42074133, PMCID: PMC13116552, DOI: 10.3390/ijms27083489.Peer-Reviewed Original ResearchCitationsAltmetricDendritic spine dysgenesis in spinal cord injury: A structural contributor to pain and spasticity
Kauer S, Effraim P, Bangalore L, Waxman S, Tan A. Dendritic spine dysgenesis in spinal cord injury: A structural contributor to pain and spasticity. Experimental Neurology 2026, 399: 115679. PMID: 41654287, DOI: 10.1016/j.expneurol.2026.115679.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial
Geva M, Goldberg Y, Leitner M, Cruz-Herranz A, Hand R, Chen K, Emek N, Tan A, Paganoni S, Berry J, Macklin E, Shefner J, Cudkowicz M, Hayden M. Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial. Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration 2025, 27: 432-444. PMID: 41406304, DOI: 10.1080/21678421.2025.2597935.Peer-Reviewed Original ResearchCitationsAltmetricPridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases
Emek N, Tan A, Geva M, Fekete A, Abate C, Hayden M. Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases. Pharmaceuticals 2025, 18: 1900. PMID: 41471389, PMCID: PMC12736105, DOI: 10.3390/ph18121900.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricCaudal Granular Insular Cortex to Somatosensory Cortex I: A Critical Pathway for the Transition of Acute to Chronic Pain
Ball J, Finch M, Taylor J, Smith Z, Rocha I, Green-Fulgham S, Rowe E, Dragavon J, McNulty C, Dreher R, Siddique I, Davis G, Tan A, Baratta M, Barth D, Watkins L. Caudal Granular Insular Cortex to Somatosensory Cortex I: A Critical Pathway for the Transition of Acute to Chronic Pain. Journal Of Neuroscience 2025, 46: e1306252025. PMID: 41402127, PMCID: PMC12873647, DOI: 10.1523/jneurosci.1306-25.2025.Peer-Reviewed Original ResearchCitationsAltmetricMesenchymal stem cells reverse disease-specific abnormalities in nociceptive regions of the brain
Fukushi R, Sasaki M, Obara H, Kurihara K, Hirota R, Morita T, Teramoto A, Yamashita T, Tan A, Waxman S, Kocsis J, Honmou O. Mesenchymal stem cells reverse disease-specific abnormalities in nociceptive regions of the brain. Brain Communications 2025, 8: fcaf494. PMID: 41509715, PMCID: PMC12776362, DOI: 10.1093/braincomms/fcaf494.Peer-Reviewed Original ResearchAltmetricPridopidine in early-stage manifest Huntington’s disease: a phase 3 trial
Reilmann R, Feigin A, Rosser A, Kostyk S, Saft C, Cohen Y, Schuring H, Hand R, Tan A, Chen K, Feng W, Navon-Perry L, Cruz-Herranz A, Syltevik C, Boot D, Squitieri F, Kayson E, Mehra M, Goldberg Y, Geva M, Hayden M. Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial. Nature Medicine 2025, 31: 3780-3789. PMID: 40913168, PMCID: PMC12618238, DOI: 10.1038/s41591-025-03920-3.Peer-Reviewed Original ResearchCitationsAltmetricTranslational Pain Research: Dendritic Spines as Therapeutic Targets
Benson C, Waxman S, Tan A. Translational Pain Research: Dendritic Spines as Therapeutic Targets. 2025, 447-470. DOI: 10.1007/978-3-031-89307-0_23.ChaptersAntidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis
Geva M, Goldberg Y, Schuring H, Tan A, Long J, Hayden M. Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis. Movement Disorders 2025, 40: 928-937. PMID: 40099482, PMCID: PMC12089908, DOI: 10.1002/mds.30164.Peer-Reviewed Original ResearchCitationsAltmetricThe Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease
Goldberg Y, Navon-Perry L, Cruz-Herranz A, Chen K, Hecker-Barth G, Spiegel K, Cohen Y, Niethammer M, Tan A, Schuring H, Geva M, Hayden M. The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease. CNS Drugs 2025, 39: 485-498. PMID: 40055280, PMCID: PMC11982116, DOI: 10.1007/s40263-025-01171-x.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity AVI Publishing Inc.
09/01/2009 - 06/20/2012Professional OrganizationsEditorDetailsJournalist and editorial service for commercial magazineactivity Phase Five Communications Inc./Grey Healthcare Group
10/01/2008 - 10/31/2009Professional OrganizationsConsultant
Honors
honor Travel Award, 12th World Congress on Pain
08/01/2008International AwardInternational Association for the Study of Pain (IASP)DetailsUnited Stateshonor Research Work Award, Public Education/Communication Committee
08/01/2008International AwardSociety for NeuroscienceDetailsUnited Stateshonor Keystone Symposia Scholarship
10/01/2005National AwardNINDSDetailsUnited States
Get In Touch
Copy Link